BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 27, 2026
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

VBAS touted as a major change for neurosurgical retraction tech

March 26, 2010
By Omar Ford

Spirocor pulse oximeter test is effective in detecting CAD

March 25, 2010
By Omar Ford

Tiny ultrasound device could be novel therapy in treating arthritis

March 24, 2010
By Omar Ford
There are few treatment options for people who suffer from chronic pain or arthritis outside of pharmaceuticals, and those options can sometimes prove to be harmful if used for an extended period of time. But what if there was a better option with a significant amount of the side effects reduced? (Medical Device Daily)
Read More

Women survive heart attacks with more invasive therapies

March 22, 2010
By Omar Ford
ATLANTA — When it comes down to the rate at which men and women survive heart attacks and other cardio illnesses, there is a huge discrepancy between the two groups. A recent study shed more light on this discrepancy and revealed that women are more likely to survive a heart attack if they received the same level of therapy as males. (Medical Device Daily)
Read More

Genetic test gives greater insight into proper Warfarin dosage

March 19, 2010
By Omar Ford

Panel: Next Generation DES safer than previous iterations

March 18, 2010
By Omar Ford
ATLANTA — While the jury is still out on drug-eluting stents being safer and more effective than bare metal stents (Medical Device Daily, March 16, 2010), there is one question about the popular devices that can be conclusively answered. That is that the latest generation of DES seem to be much safer than their predecessors, according to a panel at the 59th Annual Scientific Session of the American College of Cardiology (ACC; Washington). (Medical Device Daily)
Read More

Bare-Metal stents better than DES? Research results mixed on answer

March 17, 2010
By Omar Ford

Healthcare reform debate still a key topic at ACC

March 16, 2010
By Omar Ford

From defensive program to tumors; Star Wars tech treats breast cancer

March 15, 2010
By Omar Ford

LenSx takes big steps toward femtosecond laser utilization

March 12, 2010
By Omar Ford
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2026.
  • Drug capsule spilling onto brain

    Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

    BioWorld Science
    Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
  • Cell nucleus architecture

    4D Nucleome opens new wave of gene regulation research, discovery

    BioWorld
    After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
  • Business pipeline illustration

    Transcripta Bio raises funding to advance neuro pipeline

    BioWorld Science
    Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
  • EMA logo on mobile screen, vials, syringes

    Daybu readthrough in EU? Zevra’s NPC bid flounders

    BioWorld
    Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing